Quick Answer
TherapeuticsMD, Inc. reported Total Revenue of $1.76 million for fiscal year 2024.
TherapeuticsMD, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | $1.76M +35.3% |
$1.30M -98.1% |
$69.96M +2619.1% |
$2.57M -96.0% |
$64.87M +30.7% |
| Revenue (ASC 606) | — | — | — | $69.96M +2619.1% |
$2.57M -96.0% |
$64.87M +30.7% |
| Net Income | -$569.0K +73.9% |
-$2.18M +78.8% |
-$10.28M -109.2% |
$112.00M +165.0% |
-$172.41M +6.1% |
-$183.52M -4.2% |
| Diluted EPS | -$0.05 +73.7% |
-$0.19 +80.8% |
-$0.99 -108.3% |
$11.96 +155.2% |
-$21.66 | — |
| Total Assets | $37.66M -3.0% |
$38.82M -10.4% |
$43.31M -52.1% |
$90.46M -46.6% |
$169.47M -6.7% |
$181.61M -31.7% |
| Cash and Equivalents | — | $5.06M +16.9% |
$4.33M | — | — | — |
| Long-Term Debt | — | — | — | — | $0.00 -100.0% |
$237.70M +22.1% |
| Stockholders Equity | $26.88M -1.8% |
$27.37M -6.5% |
$29.29M -16.7% |
$35.14M +137.5% |
-$93.62M +24.5% |
-$124.00M -1447.7% |
| R&D Expense | — | — | — | — | $7.09M -32.1% |
$10.43M -47.3% |
| Operating Income | -$4.39M +28.2% |
-$6.11M +28.3% |
-$8.52M -815.6% |
$1.19M +101.5% |
-$79.58M +48.8% |
-$155.54M -2.9% |
| Gross Profit | — | — | $1.30M -98.1% |
$68.57M +5755.3% |
$1.17M -97.6% |
$48.90M +12.9% |
| Shares Outstanding | 11.57M +0.4% |
11.53M +0.0% |
11.53M +21.4% |
9.50M +10.5% |
8.60M -97.1% |
299.76M +10.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2023 | -$53.0K | -115.0% | -112.1% |
| Revenue (ASC 606) | September 30, 2023 | -$53.0K | -115.0% | -112.1% |
| Net Income | September 30, 2025 | $152.0K | +125.0% | -72.4% |
| Diluted EPS | September 30, 2025 | $0.01 | +120.0% | -80.0% |
| Total Assets | September 30, 2025 | $38.67M | -2.2% | +0.4% |
| Cash and Equivalents | March 31, 2025 | $5.75M | — | +13.6% |
| Long-Term Debt | September 30, 2021 | $171.74M | -27.6% | -2.0% |
| Stockholders Equity | September 30, 2025 | $27.44M | +1.3% | +0.6% |
| R&D Expense | September 30, 2022 | $1.11M | -30.7% | -29.6% |
| Operating Income | September 30, 2025 | -$862.0K | +24.0% | -24.0% |
| Gross Profit | September 30, 2023 | -$53.0K | — | -112.1% |
| Shares Outstanding | September 30, 2025 | 11.57M | +0.4% | +0.0% |
- TherapeuticsMD, Inc. reported Total Revenue of $1.76 million for fiscal year 2024.
- TherapeuticsMD, Inc. showed an increase of +35.3% in Total Revenue compared to the prior fiscal year.
- TherapeuticsMD, Inc. reported Revenue (ASC 606) of $69.96 million for fiscal year 2022.
- TherapeuticsMD, Inc. showed an increase of +2619.1% in Revenue (ASC 606) compared to the prior fiscal year.
- TherapeuticsMD, Inc. reported Net Income of -$569.0 thousand for fiscal year 2025.
- TherapeuticsMD, Inc. showed an increase of +73.9% in Net Income compared to the prior fiscal year.
- TherapeuticsMD, Inc. reported Diluted EPS of $0.05 per share (loss) for fiscal year 2025.
- TherapeuticsMD, Inc. showed an increase of +73.7% in Diluted EPS compared to the prior fiscal year.
- TherapeuticsMD, Inc. reported Total Assets of $37.66 million for fiscal year 2025.
- TherapeuticsMD, Inc. showed a decrease of -3.0% in Total Assets compared to the prior fiscal year.
- TherapeuticsMD, Inc. reported Cash and Equivalents of $5.06 million for fiscal year 2024.
- TherapeuticsMD, Inc. showed an increase of +16.9% in Cash and Equivalents compared to the prior fiscal year.
- TherapeuticsMD, Inc. reported Long-Term Debt of $0.00 for fiscal year 2021.
- TherapeuticsMD, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- TherapeuticsMD, Inc. reported Stockholders Equity of $26.88 million for fiscal year 2025.
- TherapeuticsMD, Inc. showed a decrease of -1.8% in Stockholders Equity compared to the prior fiscal year.
- TherapeuticsMD, Inc. reported R&D Expense of $7.09 million for fiscal year 2021.
- TherapeuticsMD, Inc. showed a decrease of -32.1% in R&D Expense compared to the prior fiscal year.
- TherapeuticsMD, Inc. reported Operating Income of -$4.39 million for fiscal year 2025.
- TherapeuticsMD, Inc. showed an increase of +28.2% in Operating Income compared to the prior fiscal year.
- TherapeuticsMD, Inc. reported Gross Profit of $1.30 million for fiscal year 2023.
- TherapeuticsMD, Inc. showed a decrease of -98.1% in Gross Profit compared to the prior fiscal year.
- TherapeuticsMD, Inc. reported Shares Outstanding of 11.57 million shares for fiscal year 2025.
- TherapeuticsMD, Inc. showed an increase of +0.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: